Live AI Dream Session, Vol. 3: Trustworthy AI in Practice with Sarath Kuravi and Dr. Shonraj Ballae • Nov 10 | 11:00 AM EST Reserve Your Seat Claim Free Seat

Reserve Your Seat
Intuceo
Book a Briefing

Tag: Model Governance

Best Enterprise MLOps Platforms in 2026: How Fortune 1000 Teams Are Choosing Between Databricks, SageMaker, and Vertex AI

Posted on by Intuceo
Machine learning operations (MLOps) choices at Fortune 1000 scale tend to outlive the teams that make them, so any shortlist of enterprise MLOps platforms deserves scrutiny. Ask data leaders to name the best MLOps platforms for enterprise in 2026 and the answer sounds familiar: Databricks, Amazon SageMaker AI, and Google’s Vertex AI, plus Azure Machine Learning wherever Microsoft anchors the estate. Yet the services behind those names changed materially over the past year, and most enterprise MLOps platform comparisons still describe the earlier versions. An enterprise MLOps platform is the service that tracks experiments, registers and approves models, deploys them, and monitors them in production under the company’s security and audit controls.
This guide covers what changed, where each option earns its place, and how large enterprises are settling the Databricks vs SageMaker vs Vertex AI question in practice.
Short answer: Databricks fits enterprises whose governed data already lives in a lakehouse, especially across several clouds. Amazon SageMaker AI fits AWS-standardized estates with strong infrastructure teams. Gemini Enterprise Agent Platform (formerly Vertex AI) fits BigQuery-centered teams building agents. Azure Machine Learning fits Microsoft-anchored estates. Many Fortune 1000 companies run a split stack with one registry of record.

What Changed in 2026 for Databricks, SageMaker AI, Vertex AI, and Azure ML?

Four shifts change how an enterprise ML platform evaluation should read this year.

Vertex AI Is Now Gemini Enterprise Agent Platform

On April 22, 2026, Google renamed its ML services. Vertex AI Pipelines became Agent Platform Pipelines, Vertex AI Model Registry became Agent Platform Model Registry, and Vertex AI Model Monitoring became Model Monitoring on Agent Platform [1]. The capabilities carried over, but the framing shifted toward agents: the same release introduced Agent Runtime, Agent Identity, and Agent Registry. In September 2026, Google released a new Agent Platform software development kit (SDK) for Python. It moves generative AI and agent code out of the older google-cloud-aiplatform package and comes with a migration guide [1]. Teams with large Vertex codebases should check how far that change reaches into their code. They should also confirm how much of the roadmap still serves predictive, tabular ML.

SageMaker AI Now Offers Serverless MLflow

In December 2025, Amazon Web Services (AWS) announced serverless MLflow in SageMaker AI at no additional charge, integrated with SageMaker Model Registry and SageMaker Pipelines [2]. Teams no longer have to size and maintain tracking servers to track experiments.

Unity Catalog Is Now the Default Databricks Model Registry

Under MLflow 3, models register to Unity Catalog by default. That extends centralized access control, auditing, lineage, and cross-workspace discovery to registered models [3]. A model is now governed by the same privileges as the tables that trained it.

Azure Machine Learning Now Sits Within Microsoft Foundry

Microsoft now presents Azure Machine Learning within Microsoft Foundry’s documentation as the track for model training, pipelines, and automated ML [4]. Foundry itself concentrates on agents and generative artificial intelligence (AI) applications.
Together, these changes make experiment history more portable than it was a year ago. Registries, permissions, and serving endpoints remain tied to each provider.

Databricks vs SageMaker AI vs Vertex AI: Where Each Enterprise MLOps Platform Fits

Here is how the four platforms compare at a glance.
Platform Best fit Model registry and governance Clouds Watch for
Databricks Lakehouse-centered, multi-cloud estates Unity Catalog (default under MLflow 3) AWS, Azure, Google Cloud Workspaces without Unity Catalog
Amazon SageMaker AI AWS-standardized estates SageMaker Model Registry, IAM AWS Overlap with Unified Studio and Bedrock
Gemini Enterprise Agent Platform (formerly Vertex AI) BigQuery-centered teams building agents Agent Platform Model Registry Google Cloud Renamed services, SDK migration
Azure Machine Learning Microsoft-anchored estates Azure Machine Learning model registry, Azure role-based access control Azure Split between Azure Machine Learning and Foundry

Databricks: Strongest When the Lakehouse Is the System of Record

Databricks suits enterprises whose features, training data, and reporting already live in Delta tables within an enterprise data lakehouse. Databricks MLflow for enterprise use is compelling because model governance inherits AI data governance. A model registered in Unity Catalog carries lineage back to its training tables, and promotion between environments runs through catalog privileges with no separate approval tool [3]. Databricks also runs on AWS, Azure, and Google Cloud, which matters for groups operating more than one cloud.
  • Best fit: demand forecasting, fraud scoring, churn, and other feature-heavy predictive models built on shared enterprise data.
  • Watch for: Unity Catalog adoption. Workspaces without it fall back to the legacy workspace registry and lose these governance features [3].

Amazon SageMaker AI: Strongest When AWS Is the Operating Fabric

SageMaker AI fits enterprises that already run identity, networking, and security operations on AWS and want ML to inherit them. Its strength is the breadth of managed training and inference options, from scheduled batch jobs to real-time endpoints and large distributed training runs on SageMaker HyperPod. All of it runs under the AWS Identity and Access Management (IAM) and virtual private cloud (VPC) controls the security team already audits. Serverless MLflow [2] removed one of the operational chores that used to make SageMaker feel assembled from parts.
  • Best fit: custom model training and fine-tuning, high-volume real-time inference, and organizations with a mature internal engineering function for ML infrastructure.
  • Watch for: SageMaker AI, SageMaker Unified Studio, and Amazon Bedrock cover some of the same ground. Teams need an explicit decision on which one owns model governance.

Vertex AI (Now Gemini Enterprise Agent Platform): Strongest When BigQuery and Agents Set the Agenda

Google’s offering suits organizations whose analytics already center on BigQuery and whose next ML investments combine predictive models with generative AI and agents. The AWS SageMaker vs Vertex AI comparison now turns on that direction. Google has put agent identity, a central agent registry, and an agent gateway in the same service that hosts pipelines and model monitoring [1]. That shortens the path from a scoring model to an agent that acts on its output.
  • Best fit: analytics teams whose data already sits in BigQuery, and enterprises building agentic workflows on top of existing predictive models.
  • Watch for: Renamed services and the SDK migration [1], plus a roadmap now weighted toward agents.

Azure Machine Learning: Strongest When Microsoft Anchors the Estate

Azure Machine Learning suits enterprises whose cloud operations already run on Microsoft. Microsoft now documents it within Microsoft Foundry as the track for model training, pipelines, and automated ML, while Foundry concentrates on agents and generative AI [4].
  • Best fit: Microsoft-centered estates that want ML alongside their other Azure services.
  • Watch for: an explicit decision on which work belongs in Azure Machine Learning and which in Foundry.

How Fortune 1000 Teams Choose an Enterprise MLOps Platform

Large enterprises rarely decide on feature checklists. Three anchors settle most choices, roughly in this order:
  • Data gravity: MLOps goes where governed feature data already lives, because moving large datasets to suit a tool costs more than adapting the tool.
  • Commercial gravity: Spend that counts toward an existing cloud commitment is easier to approve than a new vendor contract. Databricks can qualify too: Azure Databricks is billed through Azure, and on AWS it can be purchased through AWS Marketplace [5].
  • Audit gravity: Under regulated MLOps governance, the model risk or compliance function has to sign off on the registry, approval trail, and access model.
When those anchors point in different directions, three stack patterns recur.
Pattern Typical shape Where it works Trade-off
Lakehouse-anchored Databricks for features, training, registry, and serving Multi-cloud estates; data-heavy predictive ML A second bill to reconcile on classic compute
Cloud-native SageMaker AI or Agent Platform across the full lifecycle Single-cloud enterprises with strong infrastructure teams Deeper dependence on one provider’s services
Split stack Databricks for data and features; SageMaker AI or Agent Platform for serving and generative AI near applications Enterprises whose applications run on one cloud while data runs on a lakehouse Two registries and two permission models to keep aligned
There is no universal best enterprise MLOps platform or stack for a Fortune 1000 company. The split stack appeals because it respects all three anchors. It holds up only when one registry is formally named the registry of record for approved models.

What Drives MLOps Cost at Enterprise Scale?

List price rarely decides MLOps cost in the enterprise. Idle real-time endpoints, duplicated data copies across stacks, and spend that sits outside the ML service’s own invoice move the total far more. That last factor is built into how Databricks bills. On classic compute, Databricks platform costs and cloud infrastructure costs come from separate data sources and must be reconciled. On serverless, infrastructure is bundled into the Databricks charge, though storage stays with the cloud provider [5]. Databricks has released an open-source solution that joins the two views. It names General Motors among the companies using this approach to understand their Databricks spend [5].
SageMaker AI and Agent Platform charges land on the same cloud invoice as the rest of the estate. That simplifies attribution, but ML spend can disappear among other services unless tagging is disciplined. The most reliable comparison takes one tabular model and one generative AI use case through training, deployment, monitoring, and a retraining cycle on each shortlisted option, then compares the full bill. Intuceo’s costed MLOps fit assessment follows the same approach.

How Intuceo Helps Enterprises Choose and Run an MLOps Platform

Intuceo works across AWS, Azure, and Google Cloud. Its data engineering teams have hands-on depth in Databricks Unity Catalog, MLflow, Feature Store, and model serving, alongside Amazon SageMaker and Azure Machine Learning. They are PhD-led and approach the choice as an operating decision. They map where governed data sits, which cloud commitments apply, and what evidence auditors expect, much as an AI readiness assessment would. Then they build production MLOps pipelines with drift monitoring, automated retraining, and interpretability in place from the first release.

Get a costed MLOps fit assessment

Bring your current data estate and two candidate use cases. You leave with a recommended stack, a registry-of-record decision, and a migration plan sized to your cloud commitments.
Book an MLOps Fit Assessment

Frequently Asked Questions

There is no single best platform. Databricks, SageMaker AI, and Gemini Enterprise Agent Platform (formerly Vertex AI) each lead in a different setup, depending on where the company’s anchors sit.
  • Databricks: tends to fit when a lakehouse already holds governed data across more than one cloud.
  • SageMaker AI: tends to fit AWS-standardized estates with strong infrastructure teams.
  • Gemini Enterprise Agent Platform (formerly Vertex AI): tends to fit when BigQuery is central and agents are on the near-term roadmap.
For groups built through acquisitions, the bigger question is often whether to standardize at all. A shared registry of record usually delivers more control than forcing every business unit onto one vendor.
Both now run managed MLflow, so day-to-day experiment tracking looks similar. The difference is in the registry.
On Databricks, models register into Unity Catalog and share permissions, lineage, and audit logs with data. Promotion uses environment-specific catalogs and model aliases, because Unity Catalog does not support the older Staging and Production stages [3].
On SageMaker AI, serverless MLflow connects to SageMaker Model Registry and Pipelines, and access control runs through IAM [2].
The practical test is which one your governance should run through: the data catalog or the cloud account.
Give the most weight to criteria that are expensive to reverse:
  • Registry of record: which system holds approved model versions and their lineage.
  • Identity and access: whether ML permissions reuse the identity system your auditors already test.
  • Serving profile: the mix of batch scoring, real-time endpoints, and agent workloads, and what each costs at your volumes.
  • Portability: how much pipeline code and metadata, MLflow runs included, would move if you changed providers.
Test each one against your own workloads in a time-boxed bake-off, because vendor demos rarely surface registry or permission friction.
Neither has a blanket advantage. Both list their core ML services within FedRAMP authorization scope, so the choice turns on data location, identity, and validation.
Google lists Agent Platform training, pipelines, model registry, and model monitoring among services in scope for its Federal Risk and Authorization Management Program (FedRAMP) and Department of Defense authorizations [6]. Microsoft lists Machine Learning among Azure services in FedRAMP High audit scope [7].
The deciding factors are usually:
  • Data location: Where regulated data already resides, a question we cover in our AWS vs Azure comparison for HIPAA healthcare analytics.
  • Identity: which identity system the compliance team audits.
  • Validation: whether your configured environment, including customer-managed encryption keys and private networking, can be validated.
An authorization covers the provider’s service; validation covers your configuration of it. For how teams handle this in practice, see our guide to MLOps in healthcare and pharma.

MLOps in Healthcare and Pharma: How Teams Govern Models in Production

Posted on by Intuceo
A model that classifies adverse event reports or stratifies patient risk becomes a regulated computerized system the day it goes live, with one complication that conventional validation never had to absorb: its performance depends on data it has not seen yet. The records it produces still carry the same integrity, traceability, and privacy obligations as a batch record or a claims file. MLOps in healthcare and pharma is the discipline that keeps those two facts aligned, so that every model in production can be reproduced, explained, and defended at inspection.
Machine learning operations (MLOps) already gives teams the raw mechanics: pipelines, experiment tracking, model registries, and monitoring. This guide covers what healthcare and pharma teams add on top of those mechanics, stage by stage, building on our broader guide to MLOps for regulated industries.
What is MLOps in healthcare and pharma?
MLOps in healthcare and pharma is the practice of running machine learning pipelines so every production model can be reproduced, explained, and defended at inspection. It adds regulated controls to standard MLOps: validated releases, Part 11 audit trails, HIPAA safeguards, and change control that is approved before retraining begins.

Key Takeaways

  • Part 11 and HIPAA are binding today, while FDA, EMA, and EU Annex 22 AI guidance shapes the evidence inspectors expect to see.
  • A model’s context of use and risk rating set how deep its validation needs to go.
  • Each pipeline stage, from data preparation to change control, should generate its own evidence automatically.
  • Retraining protocols, including triggers, acceptance criteria, and rollback, are approved before the first deployment.
  • Accountability for AI-assisted decisions stays with named people, backed by review queues and logged overrides.

Which Regulations Apply to MLOps in Healthcare and Pharma?

No single regulation governs machine learning (ML) in healthcare and life sciences. Teams assemble their obligations from records rules, privacy law, the good practice regulations collectively known as GxP (manufacturing, clinical, laboratory, and pharmacovigilance), and artificial intelligence (AI) guidance that is still maturing. The documents below carry the most weight for models in production.
Source Status What it asks of the pipeline
21 CFR Part 11 (Code of Federal Regulations) Binding regulation Validated systems, secure time-stamped audit trails for record creation, modification, and deletion, and change control over systems documentation[1]
Health Insurance Portability and Accountability Act (HIPAA) Security Rule, 45 CFR 164.312 Binding regulation Access control, integrity safeguards, and audit controls that record and examine activity in systems holding electronic protected health information (ePHI)[2]
U.S. Food and Drug Administration (FDA) guidance on AI for drug and biological decision-making, January 2025 Draft, nonbinding A risk-based credibility assessment for a defined context of use, with life cycle maintenance after deployment[3]
FDA and European Medicines Agency (EMA) Guiding Principles of Good AI Practice, January 2026 Joint principles Traceable data provenance in line with GxP, risk-based performance assessment, and scheduled monitoring for issues such as data drift[4]
FDA Predetermined Change Control Plan (PCCP) guidance for AI-enabled device software Final, nonbinding Pre-specified modifications, a protocol to develop, validate, and implement them, and an impact assessment[5]
European Union (EU) Good Manufacturing Practice (GMP) Annex 22, Artificial Intelligence Consultation draft Continuous oversight of AI systems, including change control, performance monitoring, and human review procedures[6]
The practical reading of the table is that Part 11 and HIPAA are enforceable today, while the AI-specific documents describe the evidence inspectors will increasingly expect to see. FDA AI compliance in 2026 therefore means satisfying binding records and privacy rules with evidence organized the way the AI guidance describes it.

How Does FDA’s Context of Use Shape AI Model Validation?

FDA’s draft guidance anchors validation to a defined question and a context of use (COU), then rates model risk on two factors. Model influence is the weight the model’s output carries in the decision relative to other evidence. Decision consequence is the significance of an adverse outcome if that decision turns out to be wrong.[3]
The guidance’s own example of high risk on both counts is a model used to decide which trial participants can skip inpatient monitoring after dosing. A model that ranks literature for a human reviewer would sit far lower, and its credibility plan can be lighter in proportion.
This framing answers how FDA expects AI models to be validated and monitored in clinical settings: through evidence scaled to risk, defined before deployment, and maintained for as long as the model is in use. Operationally, the COU statement, risk rating, and acceptance criteria belong in the model registry as metadata on every version. When an inspector asks why a model was validated the way it was, the answer then travels with the model rather than sitting in a document nobody can locate.

How to Govern MLOps in Healthcare and Pharma, Stage by Stage

Implementing MLOps in healthcare and pharma comes down to deciding what evidence each stage must produce, then making the pipeline produce it automatically.

How Is MLOps in Healthcare Different From Standard MLOps?

Standard MLOps and its regulated form share the same tooling. The difference is the evidence each step has to leave behind.
Area Standard MLOps MLOps in healthcare and pharma
Data Versioned datasets Immutable, hashed snapshots linked to each model version, with ePHI kept in access-controlled zones and de-identified before experimentation
Validation Metrics reviewed after training Acceptance criteria fixed before training, tested on held-out data, with the report assembled from pipeline metadata
Release Automated promotion to production An approval signature bound to a specific model version, with a Part 11 audit trail of who approved what and when
Monitoring Drift alerts Thresholds set by the COU risk rating; a breach opens a quality investigation with documented root cause
Retraining Scheduled or triggered automatically A retraining protocol or PCCP, approved in advance, covering triggers, data windows, acceptance criteria, and rollback
Accountability The ML team A named owner, risk tier, and review date in a model inventory, with human review of AI outputs that inform regulated decisions

Stage 1: Data Preparation and Provenance

The FDA and EMA principles ask that data provenance, processing steps, and analytical decisions be documented in a traceable, verifiable manner consistent with GxP.[4] In practice, every training set becomes an immutable, hashed snapshot that a model version points to, so retraining on identical data is always possible. A HIPAA-compliant ML pipeline adds two controls at this stage: ePHI stays inside access-controlled zones with logged activity, and data is de-identified before it reaches experimentation environments that have no need for identifiers.

Stage 2: Training and Validation

GxP MLOps for pharma uses the same automation as conventional MLOps, operated under a risk-based quality system so the automation itself generates the evidence. Each training run captures the code commit, container image, parameters, and dataset version without manual entry. Performance is tested against acceptance criteria fixed before training, on held-out data the team did not tune against, and the validation report is assembled from pipeline metadata instead of being written after the fact.

Stage 3: Release and Approval Under Part 11

Promotion from staging to production is where 21 CFR Part 11 AI validation concentrates, starting with validation of the systems involved (§11.10(a)). The promotion is an electronic record: it needs an approval signature bound to a specific model version (§11.70), and an audit trail showing who approved what and when (§11.10(e)). Part 11 also requires change control over systems documentation (§11.10(k)), which in an MLOps setting extends to pipeline definitions and infrastructure code.[1]

Stage 4: Production Monitoring and Drift

Monitoring covers three signals: shifts in input distributions, shifts in output distributions, and realized performance once ground truth arrives, such as adjudicated adverse event cases or confirmed readmissions. In healthcare MLOps, alert thresholds should follow the COU risk rating. A breach opens an investigation under the quality system with documented root cause, which keeps automatic retraining from silently masking a problem. Prediction logs are records in their own right and need retention periods aligned with the underlying regulation.

Stage 5: Change Control and Retraining

Every retrained model is a new version, and the pharma AI model lifecycle depends on deciding in advance how much revalidation each type of change requires. For AI-enabled medical devices, a PCCP lets manufacturers describe planned modifications, the methodology to develop, validate, and implement them, and an assessment of their impact, so pre-authorized changes do not each need a new marketing submission.[5] The draft EU Annex 22 points in the same direction for manufacturing, pairing change control with ongoing performance monitoring.[6] The retraining protocol, covering triggers, data windows, acceptance criteria, and rollback, should be approved before the first deployment rather than drafted during the first incident.

Evidence Each Stage Must Produce

The table below summarizes what the pipeline should generate at each stage, and which requirement drives it.
Stage Evidence the pipeline must produce Main driver
Data preparation Hashed, immutable training data snapshots tied to each model version, logged ePHI access, and de-identified data for experimentation FDA and EMA principles; HIPAA Security Rule
Training and validation Code commit, container image, parameters, and dataset version for every run, plus results against pre-set acceptance criteria GxP risk-based quality system
Release and approval An approval signature bound to the model version, an audit trail of approvals, and change control over pipeline and infrastructure code 21 CFR Part 11
Production monitoring Input, output, and performance monitoring records, investigation records for threshold breaches, and retained prediction logs FDA draft AI guidance; FDA and EMA principles
Change control An approved retraining protocol or PCCP, and revalidation evidence for every new model version FDA PCCP guidance; draft EU Annex 22
Not sure your retraining protocol would hold up at inspection? Book a governance gap review.

Why Is Human Oversight Required for AI in GxP Settings?

In an April 2026 warning letter, FDA stated that when a manufacturer uses AI to help with current good manufacturing practice (CGMP) activities, any output or recommendation from an AI agent must be reviewed and cleared by an authorized human representative of the firm’s quality unit.[7] That case involved AI-drafted specifications and procedures rather than a deployed predictive model, yet the principle carries over directly: accountability for an AI-assisted decision stays with named people.
The FDA and EMA principles reinforce this by asking that performance assessment cover the complete system, including human and AI interaction.[4] For MLOps teams, that translates into review queues for low-confidence outputs, explanations surfaced at the point of review, overrides captured in the audit trail, and override rates tracked as a monitoring signal in their own right. Sound model governance for healthcare AI wraps these controls in a model inventory that records an accountable owner, a risk tier, and a periodic review date for every model in service.

How Intuceo supports governed MLOps

Intuceo is a PhD-led AI, ML, and data analytics services firm whose life sciences work includes Janssen, Ferring Pharmaceuticals, and Bausch & Lomb. Its MLOps engagements build compliance into the pipeline from the first commit, so audit logs, lineage, and validation evidence accumulate through normal operation. Deployed models carry drift monitoring, controlled retraining loops, and interpretability views designed for the reviewers who sign off on outputs.
Explainability, bias checks, and model documentation are reviewed by Intuceo’s PhD-led Board of Science & Innovation, and the iPDLC™ delivery framework places PhD-led quality gates at every transition from development to production. Teams work across MLflow, Kubeflow, and Amazon SageMaker, so governance fits the stack a client already runs instead of forcing a migration.
Running models in production ahead of an inspection or a submission? Get a governance gap review that maps each model to its context of use, audit trail coverage, and change control readiness.
Request a model governance review

Frequently Asked Questions

Pharma companies govern ML models under Part 11 by first scoping which ML artifacts count as regulated records. FDA’s Part 11 scope and application guidance ties the rule to records that other regulations, known as predicate rules, already require. It also describes enforcement discretion for certain Part 11 requirements, while predicate rule obligations stay fully in force.[8] Pharma teams therefore classify ML artifacts individually. Model outputs that feed a GxP decision, validation reports, release approvals, and training data cited in a submission are typically treated as regulated records. Exploratory notebooks stay outside scope until their results become the basis for a regulated decision.
It looks like a validated computerized system whose validation never fully closes. The International Society for Pharmaceutical Engineering (ISPE) Good Automated Manufacturing Practice (GAMP®) Guide: Artificial Intelligence was published in July 2025 for use alongside GAMP 5 (Second Edition). It covers the AI-enabled system life cycle, the responsibilities of internal and external suppliers, and ongoing monitoring and maintenance.[9] Two practical consequences follow. Cloud ML services used in GxP work need supplier assessment and infrastructure qualification. GxP and non-GxP workspaces should also be kept separate, so exploratory work cannot reach production without passing through change control.
Healthcare organizations keep ML pipelines HIPAA-compliant by de-identifying data, scrubbing identifiers from ML outputs, and holding business associate agreements (BAAs) with vendors. Most start by deciding which de-identification route applies. HIPAA recognizes two: removing a specified list of identifiers, or a formal determination by a qualified expert applying statistical and scientific methods.[10]
Beyond that, the most common leak path in healthcare MLOps is incidental. Identifiers get written into experiment logs, prediction logs, feature store snapshots, or error traces. Most of the gaps teams find in audits close with three steps: scrubbing those outputs, keeping features to the minimum the model needs, and holding BAAs with any vendor that touches ePHI.
A typical pharma MLOps stack has five layers:
  • Git for code and pipeline definitions.
  • A data versioning layer such as Data Version Control (DVC), lakeFS, or Delta Lake time travel.
  • An experiment tracker and model registry such as MLflow or the Amazon SageMaker Model Registry.
  • An orchestrator such as Kubeflow Pipelines or Apache Airflow.
  • Write-once storage for audit logs.
Whatever tools you choose, the configured system, including its procedures, access controls, and retention settings, must be validated. That is why tool selection should follow the governance design rather than come before it.
A PCCP lets makers of AI-enabled medical devices pre-specify planned model modifications, the protocol to develop, validate, and implement them, and an assessment of their impact. Once FDA authorizes the plan, changes made within it do not each need a new marketing submission.[5] For MLOps teams, the PCCP becomes the approved rulebook for retraining.